Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Business Improvement Order Issued to Novartis Japan
November 13, 2015
- “We Want to Avoid a Market Price Survey” Ahead of NHI Price Revision in FY2017: MHLW Official
November 13, 2015
- Re-Pricing of “Huge Seller” Drugs Seen Inevitable Despite Industry Opposition
November 12, 2015
- Chuikyo Leaning toward Continuing Innovation Premium for On-Patent Drugs
November 12, 2015
- Chuikyo Subcommittee Broadly OKs Price Maintenance Rule for Essential Drugs
November 12, 2015
- Financial Impact of New Drug Development Premium in FY2014 Revision Totaled 79 Billion Yen
November 12, 2015
- MHLW Floats Incentive for Hospital-Pharmacy Collaboration to Reduce Drugs Prescribed to Elderly
November 10, 2015
- JMA Reps Express Opposition to Expansion of Divided Dispensing of Long-Term Prescriptions at Chuikyo
November 10, 2015
- Novartis Fails to Report Nearly 5,500 Side Effect Cases, Biz Improvement Order Likely This Month
November 10, 2015
- MHLW Pitches Generic Incentive for In-Hospital Dispensing; Quality Worries Still Simmering at Chuikyo
November 9, 2015
- Chuikyo Wants to Stick to 14-Day Prescription Limit
November 9, 2015
- Generic Brand-Specified Prescriptions Not Permitting Substitution Decline to 15.9%: FY2015 Survey
November 9, 2015
- Editor’s Pick: Five Healthcare Policy News Headlines for October
November 6, 2015
- 4 PMDA Advisors to Resign over Conflicts of Interest
November 6, 2015
- AMED Now Taking Applications for Pre-Orphan Designation Scheme
November 6, 2015
- Chuikyo Payer Rep Urges Further Price Cuts for Long-Listed Products with Low Generic Rates
November 5, 2015
- Chuikyo Doctor Reps Positive, but Payers Wary about Industry’s Ideas on “Essential Drugs”
November 5, 2015
- AMED Aims to Give Society Access to Results of Research in Genomic Medicine: President
November 5, 2015
- Pricing Rule for Essential Drugs Top Priority in FY2016 Reform: Ex-MHLW Economic Affairs Head
November 4, 2015
- PMDA Reviewing Opdivo for Risk of Type 1 Diabetes
November 4, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…